Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
32 hedge funds and large institutions have $17.6M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 17 closing their positions.
13,000% more call options, than puts
Call options by funds: $262K | Put options by funds: $2K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
22% less funds holding
Funds holding: 41 → 32 (-9)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
88% less capital invested
Capital invested by funds: $147M → $17.6M (-$129M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$815K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$797K |
| 3 |
Renaissance Technologies
New York
|
+$707K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$631K |
| 5 |
Two Sigma Advisers
New York
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$22.3M |
| 2 |
SC
Samlyn Capital
New York
|
-$17.6M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$11.3M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.39M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.78M |
STSA Hedge Fund Activity: Q4 2022 in Review
32 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q4 2022, worth a combined $17.6M — down 88% from $147M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of STSA and 9 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Two Sigma Investments, adding an estimated $815K. The largest seller was Commodore Capital, exiting entirely with an estimated $22.3M sold.
- 32 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q4 2022, down from 41 in Q3 2022.
- Funds reported $17.6M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 88% quarter-over-quarter.
- 9 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 17 closed out, a net change of -8 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Two Sigma Investments, an estimated $815K added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Commodore Capital, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2022.